Business Segments · Operating Income (Loss)
Specialty Diagnostics — Operating Income (Loss)
Thermo Fisher Scientific Specialty Diagnostics — Operating Income (Loss) decreased by 83.2% to $313M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 81.8%, from $1.72B to $313M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026May 1, 2026
Rolls up toOperating Income
How to read this metric
An increase indicates improved operational efficiency and profitability, while a decrease signals margin pressure or rising costs.
Detailed definition
The profit or loss generated by the Specialty Diagnostics segment after deducting all operating expenses, including cost...
Peer comparison
The standard measure for comparing the operational health of business segments across the industry.
Metric ID:
tmo_segment_specialty_diagnostics_operating_income_lossHistorical Data
37 periods
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.16B | $245M | $2.28B | $310M | $2.54B | $297M | $2.82B | $353M | $2B | $243M | $1.71B | $220M | $1.86B | $208M | $1.56B | $280M | $1.58B | $297M | $1.86B | $283M | $1.85B | $264M | $1.66B | $294M | $1.82B | $299M | $1.84B | $293M | $2.02B | $273M | $1.72B | $304M | $307M | $321M | $324M | $1.86B | $313M |
| QoQ Change | — | -88.7% | +829.8% | -86.4% | +718.7% | -88.3% | +849.8% | -87.5% | +466.9% | -87.9% | +603.7% | -87.1% | +745.9% | -88.8% | +651.4% | -82.1% | +463.6% | -81.2% | +527.6% | -84.8% | +555.1% | -85.8% | +529.9% | -82.3% | +519.0% | -83.6% | +514.7% | -84.1% | +588.1% | -86.5% | +528.6% | -82.3% | +1.0% | +4.6% | +0.9% | +475.0% | -83.2% |
| YoY Change | — | — | — | — | — | — | — | — | -7.5% | -88.8% | -24.9% | -90.3% | -26.7% | -91.8% | -44.6% | -90.1% | -21.1% | -85.2% | +9.0% | -83.5% | -0.4% | -85.8% | +6.4% | -81.2% | +15.3% | -81.1% | -1.4% | -84.3% | +8.7% | -85.3% | +3.2% | -81.7% | -83.1% | -82.5% | -83.9% | +8.6% | -81.8% |
Range$208M – $2.82B
CAGR-19.3%
Avg YoY Growth-49.5%
Median YoY Growth-81.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Thermo Fisher Scientific's specialty diagnostics — operating income (loss)?
- Thermo Fisher Scientific (TMO) reported specialty diagnostics — operating income (loss) of $313M in Q1 2026.
- How has Thermo Fisher Scientific's specialty diagnostics — operating income (loss) changed year-over-year?
- Thermo Fisher Scientific's specialty diagnostics — operating income (loss) decreased by 81.8% year-over-year, from $1.72B to $313M.
- What does specialty diagnostics — operating income (loss) mean?
- The profit or loss from the Specialty Diagnostics segment's core business operations.